3,4,5,4′-trans-tetramethoxystilbene (DMU-212) modulates the activation of NF-κB, AP-1, and STAT3 transcription factors in rat liver carcinogenesis induced by initiation-promotion regimen

Molecular and Cellular Biochemistry

Volumn 391, Issue 1-2, 2014, Pages 27-35

  Cichocki, Michał ^a   Baer Dubowska, Wanda ^a   Wierzchowski, Marcin ^a   Murias, Marek ^a   Jodynis Liebert, Jadwiga ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

3,4,5,4 tetramethoxystilbene (DMU 212); AP 1; Liver carcinogenesis; N nitrosodiethylamine; NF B; STAT3

Indexed keywords

3,4,5,4' TRANS TETRAMETHOXYSTILBENE; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; DIETHYLNITROSAMINE; DMU 212; I KAPPA B ALPHA; I KAPPA B BETA; PROTEIN C FOS; PROTEIN C JUN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STAT3 PROTEIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; CYCLOOXYGENASE 2; DMU-212; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; PTGS2 PROTEIN, RAT; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA BINDING; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; ENZYME ACTIVATION; LIVER CARCINOGENESIS; LIVER CELL; MASS FRAGMENTOGRAPHY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN CONTENT; RAT; TREATMENT DURATION; ANIMAL; CARCINOGENESIS; DRUG EFFECTS; ENZYMOLOGY; LIVER; LIVER TUMOR; MALE; METABOLISM; PATHOLOGY; WISTAR RAT;

RATTUS; RATTUS NORVEGICUS;

ANIMALS; CARCINOGENESIS; CYCLOOXYGENASE 2; I-KAPPA B PROTEINS; LIVER; LIVER NEOPLASMS; MALE; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; RATS, WISTAR; STAT3 TRANSCRIPTION FACTOR; STILBENES; TRANSCRIPTION FACTOR AP-1;

EID: 84900833604     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-014-1983-9     Document Type: Article

References (35)

1. Nakata R, Takahashi S, Inoue H (2012) Recent advances in the study on resveratrol. Biol Pharm Bull 35:273-279
2. Aluyen JK, Ton QN, Tran T, Yang AE, Gottlieb HB, Bellanger RA (2012) Resveratrol: potential as anticancer agent. J Diet Suppl 9:45-56
3. Whitlock NC, Baek SJ (2012) The anticancer effects of resveratrol: modulation of transcription factors. Nutr Cancer 64:493-502
4. Sale S, Verschoyle RD, Boocock D, Jones DJN, Wilsher N, Potter GA, Farmer PB, Steward WP, Gescher AJ (2004) Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3, 4,5,4′- tetramethoxystilbene. Br J Cancer 90:736-744 (Pubitemid 38297218)
5. Piotrowska H, Myszkowski K, Ziołkowska A, Kulcenty K, Wierzchowski M, Kaczmarek M, Murias M, Kwiatkowska-Borowczyk E, Jodynis-Liebert J (2012) Resveratrol analogue 3,4,4′,5-tetramethoxystilbene inhibits growth, arrests cell cycle and induces apoptosis in ovarian SKOV-3 and A-2780 cancer cells. Toxicol Appl Pharmacol 263:53-60
6. Ma Z, Molavi O, Haddadi A, Lai R, Gossage RA, Lavasanifar A (2008) Resveratrol analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol. Cancer Chemother Pharmacol 63:27-35
7. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301-310 (Pubitemid 37328783)
8. Jochumm W, Passeguém, Erwinm E, Wagnerm F (2001) AP-1 in mouse development and tumorigenesis. Oncogene 20:2401-2412
9. Woo S, Lee BL, Yoon J, Cho SJ, Baik TK, Chang MS, Lee HE, Park JW, Kim YH, Kim WH (2011) Constitutive activation of signal transducers and activators of transcription 3 correlates with better prognosis, cell proliferation and hypoxia-inducible factor-1α in human gastric cancer. Pathobiology 78:295-301
10. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A (2010) Hepatocellular carcinoma: consensus recommendations of the national cancer institute clinical trials planning meeting. J Clin Oncol 1:3994-4005
11. Bishayee A, Barnes KF, Bhatia D, Darvesh AS, Carrol RT (2010) Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine- initiated rat hepatocarcinogenesis. Cancer Prev Res 3:753-763
12. Mbimba T, Awale P, Bhatia D, Geldenhuys WJ, Darvesh AS, Carroll RT, Bishayee A (2012) Alteration of hepatic proinflammatory cytokines is involved in the resveratrol-mediated chemoprevention of chemically induced hepatocarcinogenesis. Curr Pharm Biotechnol 13:229-234
13. Colotta F, Allavena P, Sica, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073-1081
14. Guzik TJ, Korbut R, Adamek-Guzik T (2003) Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 54:469-487 (Pubitemid 38029745)
15. Murias M, Handler N, Erker T, Pleban K, Ecker G, Saiko P, Szekeres T, Jager W (2004) Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem 12:5571-5578 (Pubitemid 39304056)
16. Das S, Lin HS, Ho PC, Ng KY (2008) The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res 25:2593-2600
17. Renard P, Ernest I, Houbion A, Art M, Le Calvez H, Raes M, Remacle J (2001) Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res 29:E21
18. Ndiaye M, Kumar R, Ahmad N (2011) Resveratrol in cancer management: where are we and where we go from here. Ann NY Acad Sci 1215:144-149
19. Szekeres T, Fritzer-Szekeres M, Saiko P, Jäger W (2010) Resveratrol and resveratrol analogues-structure-activity relationship. Pharm Res 27:1042-1048
20. Androutsopoulos VP, Ruparelia KC, Papakyriakou A, Filippakis H, Tsatsakis AM, Spandidos DA (2011) Anticancer effects of the metabolic products of the resveratrol analogue, DMU-212: structural requirements for potency. Eur J Med Chem 46:2586-2595
21. Bishayee A, Dhir N (2009) Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation. Chem Biol Interact 179:131-134
22. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M (1997) The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 9:243-252 (Pubitemid 27456391)
23. Kuo PC, Abe KY, Schroeder RA (1997) Oxidative stress increases hepatocyte iNOS gene transcription and promoter activity. Biochem Biophys Res Commun 234:289-292 (Pubitemid 27243892)
24. Calvisi DF, Pinna F, Ladu S, Pellegrino R, Muroni MR, Simile MM, Frau M, Tomasi ML, De Miglio MR, Seddaiu M, Daino L, Sanna V, Feo F, Pascale RM (2008) Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease. Carcinogenesis 29:1639-1647
25. Zykova TA, Zhu F, Zhai X, Ma WY, Ermakova SP, Lee KW, Bode AM, Dong Z (2008) Resveratrol directly targets COX-2 to inhibit carcinogenesis. Mol Carcinog 47:797-805
26. Kundu JK, Shin YK, Surh YJ (2006) Resveratrol modulates phorbol ester-induced pro- inflammatory signal transduction pathways in mouse skin in vivo: NF-kappaB and AP-1 as prime targets. Biochem Pharmacol 30:1506-1515 (Pubitemid 44666749)
27. Cichocki M, Paluszczak J, Szaefer H, Piechowiak A, Rimando AM, Baer-Dubowska W (2008) Pterostilbene is equally potent as resveratrol in inhibiting 12-O-tetradecanoylphorbol-13-acetate activated NFkappaB, AP-1, COX-2, and iNOS in mouse epidermis. Mol Nutr Food Res 52:62-70
28. Hsu T-C, Young MR, Cmarik J, Colburn (2000) Activator protein 1 (AP-1) and nuclear factor kappaB (NFκB)-dependent transcriptional events in carcinogenesis. Free Radic Biol Med 28:1338-1348 (Pubitemid 30621478)
29. Shaulian E (2010) AP-1-the jun proteins: oncogenes or tumor suppressors in disguise? Cell Signal 22:894-899
30. Vesely PW, Staber PB, Hoefler G, Kenner L (2009) Translational regulation mechanisms of AP-1 proteins. Mutat Res 682:7-12
31. Yang CW, Lee YZ, Hsu HY, Wu CM, Chang HY, Chao YS, Lee SJ (2013) c-Jun-mediated anticancer mechanisms of tylophorine. Carcinogenesis 34:1304-1314
32. Fan Q, He M, Deng X, Wu WK, Zhao L, Tang J, Wen G, Sun X, Liu Y (2013) Derepression of c-Fos caused by microRNA-139 down-regulation contributes to the metastasis of human hepatocellular carcinoma. Cell Biochem Funct 31:319-324
33. Lim CP, Cao X (1999) Serine phosphorylation and negative regulation of Stat3 by JNK. J Biol Chem 274:31055-31061
34. Musti AM, Treier M, Bohmann D (1997) Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 275:400-402 (Pubitemid 27051620)
35. Fuchs SY, Dolan L, Davis RJ, Ronai Z (1996) Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase. Oncogene 13:1531-1535 (Pubitemid 26354201)